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Abstract
Objective. Acute allergic reactions are important causes of Emergency
Department (ED) admissions. Although the current recommendations
for treatment of patients with anaphylaxis are focused on the central role
of adrenaline, evidence in support of this therapy is still scarce. We
planned a retrospective analysis of all allergic and anaphylactic reactions
managed in the ED, to assess adherence to current guidelines and clinical
outcomes.
Methods. The study population consisted of all consecutive adult patients
admitted to the ED with acute allergic reactions during the year 2013.
Overall, the final study population consisted of 589 patients, i.e., 329
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women and 260 men (55.9% vs. 44.1%, mean age 43±18 years, range 16-
96 years).
Results. Fifty-six patients were diagnosed with anaphylaxis (9.5%), 75
with angioedema (12.7%), 363 with urticaria (61.7%), and 95 with
urticaria-angioedema (16.1%). The triggers included drugs (21.9%), foods
(15.0%), hymenoptera stings (9.9%), and chemicals (4.4%), whereas a
specific cause could not be recognized in nearly half of the cases. Only 5
(8.9%) of 56 patients diagnosed with anaphylaxis received adrenaline
and no death or Intensive Care Unit (ICU) admission occurred within
one month from the acute allergic episode.
Conclusion. The results of our study suggest that anaphylaxis is widely
undertreated with adrenaline in our local ED compared to guidelines and
recommendations. Nevertheless, a favorable outcome was recorded for
all patients included in the study, even when managed with second- and
third-line treatments, as attested by the lack of deaths at 1 month and the
very limited number of hospitalizations (3/589; 0.5%), related to
comorbidities rather than to treatment failure. The strength of
recommendations contained in current guidelines should hence be
reconsidered.
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epinephrine
Introduction
Acute allergic reactions are important causes of Emergency Department
(ED) admissions, the frequency of which has exhibited an incremental
trend in the past decades. (1,2) Alongside allergic rhinitis, which is an
infrequent cause of ED visits, and asthma (i.e., a separate disease), the
most frequent types of acute allergic reactions include acute urticaria,
acute angioedema and anaphylaxis, as well as an overlap of these acute
conditions. Although acute urticaria is considered a self-limiting disease
in the vast majority of cases, it might occasionally be associated with
angioedema, or else be an important symptom of anaphylactic episodes.
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Angioedema refers to a local, reversible swelling of deep skin layers of
upper respiratory or gastrointestinal mucosa. Isolated angioedema may
seldom present with an onset of pain and tenderness, while itching is
infrequent. (4) Although angioedema does not have preferential
localization, lips, mouth, tongue, neck, larynx, pharynx, abdominal or
genital areas are the sites most frequently involved. (4) When the upper
respiratory tract is involved, the condition turns into a real clinical
emergency. As for urticaria, angioedema can also be part of the complex
clinical picture of an anaphylactic reaction.
Anaphylaxis is now defined as a severe, quickly developing and
frequently life-threatening allergic reaction. (5) Although the lifetime
prevalence of this condition approximates 2%, its frequency has
constantly increased in past years. (6) Importantly, uncertainty still
exists about the precise definition, so that only 1% of ED admissions for
acute systemic allergic reactions are correctly diagnosed as anaphylaxis,
whereas most cases are classified as “acute allergic reactions” or “acute
hypersensitivity reactions”. (7,8) From a clinical perspective, anaphylaxis
should also be regarded as a continuous rather than a dichotomous state,
and this probably entails different management strategies .
Although the current recommendations for treatment of patients with
anaphylactic reactions are focused on the central role of adrenaline (also
known as epinephrine), the evidence in support of this therapeutic
approach is scarce due to the lack of well-designed controlled trials. (9-
12) The therapeutic recommendations for use of adrenaline in
anaphylaxis are largely based on clinical pharmacology studies, clinical
observations, animal models, expert consensus, as well as by a
reasonable amount of anecdotal evidence. Moreover, there are some
substantial differences between guidelines, not only regarding adrenaline
utilization, but even more substantially concerning the use of oxygen,
anti-histamine and corticosteroids. (13) Therefore, we planned a
retrospective analysis of all allergic and anaphylactic reactions managed
in the ED of the University Hospital of Parma during a 1-year period, to
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assess adherence to current guidelines and clinical outcomes.
Materials and methods
The study population consisted of all consecutive adult patients admitted
to the ED of the University Hospital of Parma (Italy) with acute allergic
reactions during 2013. The facility is a 1250-bed teaching general
hospital, serving a population of approximately 435,000 inhabitants.
Information about ED visits for acute allergic reactions was acquired
from the electronic hospital database during a 1-year period (1st January
to 31st December 2013), using a double extraction key, i.e., ICD-9 codes
999, 995, 716, 708, 477, and 287 (including all the 4th and 5th digits), as
well as verbal “strings”, i.e. “allergy”, “anaphylaxis”, “urticaria”,
“angioedema”, “shock”. All cases had complete information about clinical
signs, trigger(s) (when reported), pharmacological treatment, disposition
and outcome. Patients’ outcome was monitored up to 1 month from
records included in the hospital database, telephone calls, and search in
the provincial database of deaths. The study was performed in
accordance with the Declaration of Helsinki, under the terms of relevant
local legislation.
Results
A total number of 3237 records were analyzed by two separate physicians
after first extraction, in order to exclude erroneous or dubious entries.
Children aged 16 years or younger (n=273 cases) were not included since
they are usually seen in the Pediatric Clinic of our hospital and not by
Emergency Physicians (EPs). Cases of allergic rhinitis, asthma and
chronic urticaria were also excluded (n=2376), so that the analysis was
limited to adult patients admitted with acute urticaria, acute
angioedema, urticaria-angioedema and anaphylaxis, defined according to
the recommendations of the Second symposium on the definition and
management of anaphylaxis: summary report – Second National
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis
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Network symposium, (5) and of the World Allergy Organization
guidelines for the assessment and management of anaphylaxis. (12)
Overall, the final study population consisted of 589 patients, i.e., 329
women and 260 men (55.9% vs. 44.1%, mean age 43±18 years, range 16-
96 years), representing 0.65% of all ED admissions throughout the study
period. All patients arrived to the ED prior to 12 hours from onset of
symptoms and none of them were admitted more than once for acute
allergic reactions during the study period. No patients had adrenaline
administered) before ED arrival, i.e., self-administered or from pre-
hospital providers. Fifty-six patients met the diagnostic criteria for
anaphylaxis (9.5%), 75 for angioedema (12.7%), 363 for urticaria (61.7%),
and 95 for urticaria-angioedema (16.1%). The suspected triggers of
allergic reactions were drugs (n=129; 21.9%), food (n=88; 15.0%),
hymenoptera stings (n=58; 9.9%) and chemicals (n=26; 4.4%), whereas
a specific cause could not be recognized in nearly half of cases (n=288;
48.9%). In the subgroup of patients with anaphylaxis, the triggers were
food in 17 cases (30.3%), drugs in 18 cases (32.1%), hymenoptera stings
in 5 cases (8.9%), chemicals in 5 cases (8.9%), and unknown trigger in
the remaining 11 cases (19.6%). The complete report of triggers for each
group is reported in table 1.
The 56 patients diagnosed with anaphylaxis received adrenaline in 5
cases (8.9%), whereas chlorphenamine (an anti-H1 anti-histamine drug)
was used in 35 cases (62.5%), ranitidine (an anti-H2 anti-histamine
drug) in 32 cases (57.1%), methylprednisolone in 40 cases (71.4%) (in
most cases, drugs were used in combination). In 24 cases (42.9%) other
therapeutics (mainly cristalloids, oxygen, salbutamol) were
administered. The patients with angioedema were treated with
chlorphenamine in 53 cases (70.7%), ranitidine in 24 cases (53.3%) and
methylprednisolone in 58 cases (77.3%). None of these patients received
adrenaline. Interestingly 2 (0.5%) patients with urticaria and 1 (1.1%)
with urticaria-angioedema received adrenaline. Diagnostic uncertainty
emerged from post-hoc re-evaluation of these three cases, due to the
presence of clinical features (airway involvement) which may be
consistent with a diagnosis of anaphylaxis. The triggers in the five
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patients with anaphylaxis who were treated with adrenaline were oral
levofloxacine (n=1), intramuscular ceftriaxone (n=1), oral ketoprofene
(n=1), whereas no specific cause could be established for the remaining
two cases. The complete report of treatments administered in each group
is shown in table 2. Only three patients with anaphylaxis needed
hospitalization, all for the presence of severe comorbidities (a 31 year old
women affected by Cornelia de Lange syndrome, with multiple organ
failure; an 85 year old women with diabetes, coronary artery disease and
arterial hypertension; a 77 year old man, with severe chronic obstructive
pulmonary disease). Most cases were managed in the ED Observation
Unit (EDOU) for 12-24 hours. Importantly, no death and no Intensive
care unit (ICU) admission was recorded within 1 month from ED
admission for the acute allergic episode.
Discussion
The results of our study show that anaphylaxis is widely undertreated
with adrenaline in our local ED compared to current guidelines and
recommendations, and this is in agreement with previous reports. (11,14-
17)
The significant diagnostic uncertainty is indeed one of the leading
problems for diagnosing and treating anaphylaxis. An international and
interdisciplinary group of experts attempted to establish clinical criteria
for increasing the accuracy in diagnosing anaphylaxis during the US
National Institute of Allergy and Infectious Diseases (Bethesda, MD,
USA) and the Food Allergy and Anaphylaxis Network (Chantilly, VA,
USA) convened symposia. (5) The adopted working definition was as
follows: “Anaphylaxis is a serious allergic reaction that is rapid in onset
and may cause death”. The group also proposed that anaphylaxis is likely
to be clinically present if any one of three major criteria is satisfied
within minutes to hours: (i) acute onset of illness with involvement of
skin, mucosal surface, or both, and at least one of the following:
respiratory compromise, hypotension, or end-organ dysfunction; (ii) two
or more of the following occur rapidly after exposure to a likely allergen:
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involvement of skin or mucosal surface, respiratory compromise,
hypotension, or persistent gastrointestinal symptoms; and (iii)
hypotension develops after exposure to a known allergen for that patient:
age-specific low blood pressure or decline of systolic blood pressure of
>30% compared to baseline. (5) The group concluded that these criteria
“are likely to capture more than 95% of cases of anaphylaxis”. However,
the report also states that “There undoubtedly will be patients who
present with symptoms not yet fulfilling the criteria of anaphylaxis yet in
whom it would be appropriate to initiate therapy with epinephrine, such
as a patient with a history of near-fatal anaphylaxis to peanut who
ingested peanut and within minutes is experiencing urticaria and
generalized flushing. Since anaphylaxis occurs as part of a clinical
continuum, occasionally beginning with relatively modest symptoms and
then rapidly progressing to a life-threatening condition, the delay of
treatment up to development of multi-organ symptoms must be
considered a tangible risk. Therefore, some of the authors and
Committee members of the WAO Ad Hoc Committee on Epinephrine
and Anaphylaxis recommended that any symptoms of anaphylaxis, such
as generalized pruritus, erythema, urticaria, and angioedema alone, and
any other systemic symptom including those not involving vital organs,
should be treated immediately (and as necessary) with appropriate i.m.
doses of epinephrine in an attempt to prevent the occurrence of more
severe systemic consequences. Notably, this statement is not evidence-
based, since no single study has shown that this clinical management
produces effective prevention towards systemic involvement.
Skin involvement, occurring in up to 80-90% patients with anaphylaxis,
(18) is a possible confounding factor, which creates some degree of
overlap with severe and refractory urticaria. The recent European
Guidelines for anaphylaxis (10) recommend adrenaline administration in
the presence of cardiovascular or multisystemic involvement, but the use
of this practice has a lower strength of recommendation (i.e., C and D) in
patients with limited respiratory, gastrointestinal or skin involvement.
This is mainly attributable to the fact that solid evidence is available for
the most severe clinical presentation of anaphylaxis, like hymenoptera
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sting. (19)
In our study, the percentage of unknown triggers for anaphylaxis was
19.6%, which is in agreement with that reported in the recent literature
(i.e., 20%). (20) As regards adrenaline administration, one large case
series published by an Italian centre reported that the percentage of
patients treated with this drug was 5.9%, slightly lower than in our study
(i.e., 8.9%), thus confirming the evidence of a generalized underuse of
epinephrine in this clinical setting. (15)
No prospective human studies have been published so far about the
optimal management of anaphylaxis with adrenaline, nor is information
available on dosage and bioavailability of i.m. adrenaline, when used in
this condition. Even more importantly, the incidence of adverse effects
after adrenaline administration in patients with anaphylactic reactions
remains uncertain. Some case reports and mortality reviews suggest that
a number of side-effects (especially those involving the myocardium) can
occur, are globally severe and more frequently observed in patients with
inappropriate drug dosage (i.e., overdose, or an overly rapid rate of
infusion). (21) There is also increasing awareness that the heart may be a
target organ in anaphylaxis, and that electrocardiographic changes
suggestive of ischemia, myocardial infarction or dysrhythmias may occur
even in patients not receiving adrenaline. (22-25) Interestingly, only the
i.v. route of administration was used in two published human studies,
showing a favorable effect in patients with allergic reactions
accompanied by cardiovascular collapse. (26)
A recent Cochrane review on adrenaline as a treatment of anaphylaxis
failed to report any evidence from prospective, randomized or quasi-
randomized trials on the effectiveness of this drug for emergency
management of anaphylaxis. (27) This lack of evidence was mainly
attributed to the relative infrequency of severe anaphylactic reactions,
the rapid onset, the often unexpected occurrence, as well as by the widely
accepted role of adrenaline in various clinical settings. (13,27)
In conclusion, the results of our study suggest that anaphylaxis seems to
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be widely undertreated with adrenaline in our local ED compared to
exiting guidelines and recommendations, and this is in agreement with
previous reports. (11,14-17) Nevertheless, a favorable outcome was
recorded for all patients included in this study, even when managed with
second- and third-line treatments. In fact, no death was observed at 1
month and the number of hospitalizations was very limited (3/589;
0.5%), mainly due to comorbidities rather than to treatment failure. We
hence assume that these findings should be addressed as food for
thought for reconsidering the validity of recommendations contained in
current guidelines.
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Drugs 18 (32.1) 67
(18.4)
13 (17.3) 22 (23.1) 129(21.9)
Food 17 (30.3) 52
(14.3)





12 (16.0) 11 (11.6) 58(9.9)
Chemicals 5 (8.9) 16
(4.4)
3 (4) 11 (11.6) 26(4.4)
Unknown 11 (19.6) 199
(54.8)
41 (54.6) 37 (38.9) 288(48.9)
Table 1. Triggers for allergic-anaphylactic episodes, subdivided










Adrenaline 5 (8.9) 2 (0.5) 0 1 (1.1)
Methylprednisolone 40 (71.4) 261(71.9) 58 (77.3) 78 (82.1)
Chlorfenamine 35 (62.5) 277(76.3) 53 (70.7) 84 (88.4)
Ranitidine 32 (57.1) 125(34.4) 24 (32.0) 33 (34.7)
Others 24 (42.9) 15(4.1) 3 (4.0) 6 (6.3)
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Table 2. Pharmacologic treatments given in the Emergency Department
for different types of allergic episodes. The term “others” refers to:
oxygen, salbutamol, crystalloids.
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